Wednesday February 12, 2020 0 comments
BOULDER -- Biodesix, Inc. announced the next phase of the company’s biomarker development program with Germany-based Merck and New York-based Pfizer Inc.
The companies have completed initial discovery and development of a new proteomic test that identifies likely responders to the anti-PD-L1 checkpoint inhibitor (BAVENCIO®) (avelumab).
Development efforts will now focus on transferring the test into Biodesix’s CLIA lab in Boulder for clinical phase test validation.
The new test was developed through retrospective analysis of the circulating proteome of cancer patients treated with the investigational drug candidate, utilizing the proprietary Biodesix Diagnostic Cortex™ artificial intelligence (AI) platform.
Data from the initial test discovery and development program will be presented at an upcoming scientific meeting later this year.
The Diagnostic Cortex platform is based on modern AI techniques to design clinically useful tests that are reproducible and robust, and typically use hundreds of different markers.
Based on data found in the circulating proteome and genome, Biodesix designs tests that support treatment decisions including patient selection for immunotherapies, novel therapy combinations, and alternative treatment pathways.
“We are pleased to announce this next phase in our collaboration with Merck KGaA, Darmstadt, Germany and Pfizer with the potential to extend treatment options to more patients,” said Scott Hutton, Biodesix CEO.
“This relationship combines Biodesix’s strengths in test discovery and development, artificial intelligence, and their applications to immunotherapy, with the pharmaceutical leadership of Merck KGaA, Darmstadt, Germany and Pfizer.
“The successful progression of this project is another example of how our proprietary Diagnostic Cortex AI-based biomarker platform is uniquely suited to advancing clinical research and investigating new indications for existing therapies.”
Avelumab (BAVENCIO®) in combination with axitinib is indicated in the U.S., EU, Japan and other countries for the first-line treatment of patients with advanced renal cell carcinoma (RCC).
Biodesix is a lung cancer diagnostic solutions company covering the continuum of patient care from early risk classification of lung nodules through treatment guidance in late-stage cancer.